Genzyme in the UK

Genzyme in the UK is dedicated to making a positive impact on the lives of people with serious diseases. Operating out of three locations we draw on the diverse talents of a 500-strong team. More>

Genzyme UK Announces Scottish Medicines Consortium Approval of Renvela® (sevelamer carbonate) for Use on the NHS in Scotland

Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY) welcomes the decision today by the Scottish Medicine Consortium (SMC) to approve Renvela® for use within NHS Scotland as a treatment for second-line management of hyperphosphataemia in adult patients with chronic kidney disease (CKD) receiving haemodialysis. More>

Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. More>

Exceptional Supply for Renagel & Renvela

This new section on “Our Products” page is to provide access to the Exceptional Supply form for Renagel & Renvela and is applicable only for qualified pharmacists, licensed to dispense Renagel & Renvela in the UK. More>

Search